Physician profile
Daniel A Meline
NPI 1982714960
$794,831.35
in general payments reported to CMS, 2019-2025
27 companies · $185K in 2025
The $185K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $53K · 2021: $107K · 2022: $122K · 2023: $75K · 2024: $209K · 2025: $185K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $407K · Travel and Lodging: $43K · Food and Beverage: $12K · Honoraria: $6,000 · Long Term Medical Supply Or Device Loan: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $407,211.25 |
| Travel and Lodging | $43,317.87 |
| Food and Beverage | $12,303.92 |
| Honoraria | $6,000.00 |
| Long Term Medical Supply Or Device Loan | $127.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $275,405.42 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $208,910.34 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $167,356.96 | 2024-2025 | Voquezna |
| Abbvie INC. | $85,695.27 | 2019-2025 | |
| Allergan, INC. | $48,229.44 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $7,648.34 | 2022 | |
| Genzyme Corporation | $533.55 | 2023-2025 | |
| Gilead Sciences, INC. | $283.75 | 2019-2021 | |
| Pentax of America, INC. | $127.22 | 2023 | Plasmatyphoon |
| Janssen Biotech, INC. | $114.23 | 2024-2025 | Tremfya |
| Novo Nordisk INC | $93.98 | 2019 | |
| Qol Medical, LLC | $65.57 | 2024 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.94 | 2024 | Trulance |
| Celgene Corporation | $47.03 | 2023 | Zeposia |
| Capsovision, INC. | $31.38 | 2023-2025 | Capsocam Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $28.50 | 2025 | Cuvrior |
| Ipsen Biopharmaceuticals, INC | $27.54 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $27.15 | 2023 | Entyvio |
| Abbott Laboratories | $27.07 | 2024 | Proclaim |
| Lilly USA, LLC | $21.86 | 2025 | Omvoh |
| Axonics, INC. | $19.35 | 2021 | |
| Madrigal Pharmaceuticals | $18.72 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $18.54 | 2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $17.21 | 2023 | Dupixent |
| Celltrion USA INC. | $15.10 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $12.89 | 2023 | Suflave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,173.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Meline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.